ClinicalTrials.gg
CompletedNCT02570490Updated Apr 19, 2019

Oral Sodium Fusidate (CEM-102) Versus Oral Linezolid for the Treatment of Acute Bacterial Skin and Skin Structure Infections

A Phase 3 interventional study of sodium fusidate and linezolid in Acute Bacterial Skin and Skin Structure Infections, sponsored by Arrevus Inc.. Completed at 62 sites in 2 countries. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2019-04-19.

Sponsored by Arrevus Inc. · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Nov 2016, 10 years ago, and no results have been posted to the registry; the sponsor requested a delay in submitting them in Feb 2017.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
716
Allocation
Randomized
Ages
12 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 75 studies in Cellulitis with a site in United States — 1 open to participants now, 1 under way, none of them phase 3. Cellulitis · United States.

Enrollment
10th of 65
716 · median 153
Started
2015
with 1 other
Phase 3
21 of 75
none open now
Registered
53rd of 75
by date

Among the 75 studies in Cellulitis with a site in United States, this one is the 10th largest by enrollment of the 65 interventional ones that give a count, is one of 2 that started in 2015, is one of 21 in phase 3, and was the 53rd registered.

Cellulitis

160 studies on the registry are indexed under Cellulitis; 14 are open to participants now.

Browse Cellulitis studies →

Open to participants now

1 of the 75 studies in Cellulitis with a site in United States is open now. Recruiting first, the newest first:

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 7 Cellulitis studies recruiting now, 4 set no upper age limit and 3 stop at 75 or younger; 4 take children under 18; 2 take healthy volunteers.

This study: 12 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 75 studies in Cellulitis with a site in United States, or all of them as a file.
02

Study summary

Phase 3, randomized, double-blind, multi-center efficacy and safety study to evaluate an oral CEM-102 loading dose regimen compared to oral linezolid in the treatment of subjects with ABSSSI

Read the detailed description

The primary objective is to demonstrate the non-inferiority of oral CEM-102 (loading dose regimen of 1500 mg every 12 hours for 2 doses, followed by 600 mg every 12 hours thereafter) compared to oral linezolid (600 mg every 12 hours), each administered for 10 days, for Early Clinical Response (ECR) in the intent to treat (ITT) analysis set in subjects with acute bacterial skin and skin structure infections (ABSSSI). Subjects with an ABSSSI caused by suspected or documented Gram-positive pathogen(s) at baseline will be randomized 1:1 to study treatment

03

Conditions studied

  • Acute Bacterial Skin and Skin Structure Infections

Browse trials for

Keywords

  • fusidic acid
  • skin infection
04

Who can participate

Ages eligible
12 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adolescents between 12 to 18 years old must weigh >60 kg
  • Patients diagnosed with ABSSSI with at least one systemic sign of infection
  • Diagnosed with cellulitis, major cutaneous abscess, or wound infections (traumatic or surgical)
  • Surface redness, edema or induration must be of a minimum surface area of 75 cm2, or extending ≥5 cm from the peripheral margin of the abscess
  • Suspected or documented ABSSSI caused by a Gram-positive pathogen

Exclusion criteria

Exclusion Criteria:

  • Involving a chronic diabetic foot infection (diabetic foot ulcer)
  • Involving burns
  • Involving an anatomical location (e.g. perirectal area) where the incidence of Gram-negative and/or anaerobic pathogen involvement is likely
  • Documented bacteremia associated with the current ABSSSI
  • Known severe renal impairment, as indicated by estimated \<30 mL/min (by Cockcroft-Gault calculation)
  • Evidence of significant liver disease: >3x , or direct >ULN; known cirrhosis with decompensation (i.e. Class B or C disease)
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
716 participants (actual)

Study arms

  • Experimental
    CEM-102 (Sodium fusidate)

    1500 mg by mouth every 12 hours for 2 doses, then 600 mg by mouth every 12 hours thereafter, until end of therapy (10 days total)

    Drug: sodium fusidate

  • Active comparator
    Linezolid

    600 mg by mouth every 12 hours for 10 days

    Drug: linezolid

Interventions

06

What researchers measure

Primary outcomes

  1. Proportion of subjects with a response for Early Clinical Response

    Proportion of subjects with a response for Early Clinical Response (ECR), defined as alive and achieved ≥ 20% reduction from baseline in the lesion size at 48-72 hours after start of study drug, without receipt of additional non-study antibiotic therapy.

    Time frame: 48 to 72 hours after starting treatment

Secondary outcomes

  1. Proportion of subjects with clinical success at Post-treatment Evaluation

    Proportion of subjects with clinical success at PTE, in the ITT and clinically evaluable (CE) analysis sets.

    Time frame: 7 to 14 days after end of treatment

  2. Incidence of adverse events [Safety and tolerability], Clinical Laboratory Evaluations

    Incidence of adverse events, vital sign changes, physical exam changes, and clinical laboratory evaluations will be presented by study arm

    Time frame: Up to 24 months

07

Study locations

62 sites
  • Anaheim, California 92804, United States
  • Bakersfield, California 93301, United States
  • Buena Park, California 90620, United States
  • Fountain Valley, California 92708, United States
  • La Mesa, California 91942, United States
  • La Palma, California 90623, United States
  • Long Beach, California 90813, United States
  • Los Angeles, California 90020, United States
  • Modesto, California 95350, United States
  • National City, California 91950, United States
  • Oceanside, California 92056, United States
  • Riverside, California 92506, United States
  • San Diego, California 89109, United States
  • San Diego, California 91911, United States
  • San Diego, California 91942, United States
  • San Diego, California 92114, United States
  • San Diego, California 92120, United States
  • San Dimas, California 91773, United States
  • Stockton, California 95204, United States
  • Sylmar, California 91342, United States
  • DeBary, Florida 32713, United States
  • DeLand, Florida 32720, United States
  • Doral, Florida 33126, United States
  • Doral, Florida 33166, United States
  • Hollywood, Florida 33021, United States
  • Miami Lakes, Florida 33014, United States
  • Miami, Florida 33015, United States
  • Miami, Florida 33126, United States
  • Miami, Florida 33144, United States
  • Miami, Florida 33155, United States
  • Miami, Florida 33175, United States
  • Orlando, Florida 32806, United States
  • South Miami, Florida 33143, United States
  • West Palm Beach, Florida 33401, United States
  • Augusta, Georgia 30909, United States
  • Columbus, Georgia 31904, United States
  • Savannah, Georgia 31401, United States
  • Baker, Louisiana 70714, United States
  • Eunice, Louisiana 70535, United States
  • Lutherville, Maryland 21093, United States
  • Boston, Massachusetts 02111, United States
  • Detroit, Michigan 48202, United States
  • Royal Oak, Michigan 48703, United States
  • Saint Louis, Missouri 63128, United States
  • Butte, Montana 59701, United States
  • Lincoln, Nebraska 68510, United States
  • Somers Point, New Jersey 08244, United States
  • Teaneck, New Jersey 07666, United States
  • Cincinnati, Ohio 45219, United States
  • Philadelphia, Pennsylvania 19103, United States
  • Lancaster, South Carolina 29720, United States
  • Summerville, South Carolina 29485, United States
  • Rapid City, South Dakota 57702, United States
  • Jackson, Tennessee 38305, United States
  • Gonzales, Texas 78629, United States
  • Houston, Texas 77011, United States
  • Houston, Texas 77084, United States
  • Houston, Texas 77093, United States
  • San Antonio, Texas 78229, United States
  • Splendora, Texas 77372, United States
  • San Juan, 00909-3004, Puerto Rico
  • San Juan, 00909, Puerto Rico
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2015, a primary completion of Nov 2016 and a completion of Nov 2016. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 5, 2015
First posted
Oct 7, 2015
Start
Nov 2015
Primary completionActual
Nov 2016
CompletionActual
Nov 2016
Results delay requested
Feb 20, 2017
Last update
Apr 19, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 19, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02570490
Lead sponsor
Arrevus Inc.
Responsible party
Sponsor
First posted
Oct 7, 2015
Start date
Nov 2015
Primary completion
Nov 2016
Completion
Nov 2016
Last update
Apr 19, 2019

Study contacts

Richard Pushkin, MD
study director · Melinta Therapeutics, Inc.

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Fusidic Acid

Start the discussion